Cardiovascular Systems Stock Price, News & Analysis (NASDAQ:CSII)

$24.38 0.64 (2.70 %)
(As of 11/18/2017 07:27 AM ET)
Previous Close$24.38
Today's Range$24.45 - $23.56
52-Week Range$23.00 - $33.11
Volume229,076 shs
Average Volume262,318 shs
Market Capitalization$831.89 million
P/E Ratio1219
Dividend YieldN/A
Beta2.53

About Cardiovascular Systems (NASDAQ:CSII)

Cardiovascular Systems logoCardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.


Industry, Sector and Symbol:
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Equipment
  • Sector: Medical
  • Symbol: NASDAQ:CSII
  • CUSIP: 14161910
  • Web: www.csi360.com
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 4.30%
  • Quick Ratio: 3.83%
Price-To-Earnings:
  • Trailing P/E Ratio: 1219
  • Forward P/E Ratio: -487.60
Sales & Book Value:
  • Annual Sales: $204.91 million
  • Price / Sales: 4.06
  • Cash Flow: $0.16 per share
  • Price / Cash: 156.10
  • Book Value: $3.52 per share
  • Price / Book: 6.93
Profitability:
  • Trailing EPS: ($0.06)
  • Net Income: ($1,790,000.00)
  • Net Margins: -0.93%
  • Return on Equity: 0.74%
  • Return on Assets: 0.47%
Misc:
  • Employees: 579
  • Outstanding Shares: 34,120,000
 

Frequently Asked Questions for Cardiovascular Systems (NASDAQ:CSII)

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems, Inc. (NASDAQ:CSII) announced its earnings results on Wednesday, October, 25th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The medical device company earned $49.70 million during the quarter, compared to analyst estimates of $51 million. Cardiovascular Systems had a negative net margin of 0.93% and a positive return on equity of 0.74%. Cardiovascular Systems's revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.06) earnings per share. View Cardiovascular Systems' Earnings History.

When will Cardiovascular Systems make its next earnings announcement?

Cardiovascular Systems is scheduled to release their next quarterly earnings announcement on Tuesday, January, 23rd 2018. View Earnings Estimates for Cardiovascular Systems.

What guidance has Cardiovascular Systems issued on next quarter's earnings?

Cardiovascular Systems issued an update on its second quarter earnings guidance on Wednesday, October, 25th. The company provided earnings per share (EPS) guidance of $(0.06)-(0.03) for the period, compared to the Thomson Reuters consensus EPS estimate of $0.00. The company issued revenue guidance of $52.5-54 million, compared to the consensus revenue estimate of $55.11 million.

Where is Cardiovascular Systems' stock going? Where will Cardiovascular Systems' stock price be in 2017?

5 brokers have issued 1 year price targets for Cardiovascular Systems' stock. Their predictions range from $36.00 to $40.00. On average, they anticipate Cardiovascular Systems' stock price to reach $38.00 in the next year. View Analyst Ratings for Cardiovascular Systems.

What are Wall Street analysts saying about Cardiovascular Systems stock?

Here are some recent quotes from research analysts about Cardiovascular Systems stock:

  • 1. According to Zacks Investment Research, "Cardiovascular Systems exited the first quarter of fiscal 2018 on a mixed note. The earnings compared favorably with the Zacks Consensus Estimate while revenues missed the same. Fiscal first-quarter revenues declined on a year-over-year basis owing to the impact of hurricanes. The company incurred net loss in the reported first quarter. Also, intense competition adds to the woes. On a positive note, despite the decline in revenues, the reaffirmed revenue guidance for fiscal 2018 buoys optimism. The reported net loss in the quarter was narrower than the guided range. Also, the expansion in gross margin was impressive. To note, the company is currently focusing on product innovation through R&D investments. During the quarter, the company released one-year positive data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2017 Amputation Prevention Symposium (AMP) in Chicago." (11/13/2017)
  • 2. Needham & Company LLC analysts commented, "CSII’s F1Q18 revenue and EPS beat consensus though we note that CSII had announced on 9/18/17 that it expected to miss its original guidance due to the hurricanes. F2Q18 revenue and EPS guidance were below consensus although management maintained its FY18 revenue guidance since it expects recent sales force changes to reaccelerate its coronary sales. While CSII faces its most difficult comp in F2Q18, we expect growth to accelerate in CY18 as comps begin to ease, the sales force changes improve coronary sales, CSII launches its coronary product in Japan and support products (such as guide wires) in the US." (10/26/2017)

Who are some of Cardiovascular Systems' key competitors?

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the folowing people:

  • Scott R. Ward, Chairman of the Board, President, Chief Executive Officer (Age 57)
  • Laurence L. Betterley, Chief Financial Officer (Age 63)
  • Kevin J. Kenny, Chief Operating Officer (Age 52)
  • Sandra Sedo, Chief Compliance Officer (Age 53)
  • Alexander Rosenstein, General Counsel and Corporate Secretary (Age 45)
  • Laura Gillund, Chief Talent Officer (Age 56)
  • Martha Goldberg Aronson, Independent Director (Age 50)
  • Scott A. Bartos, Independent Director (Age 54)
  • Brent G. Blackey, Independent Director (Age 58)
  • Edward M. Brown, Independent Director (Age 54)

Who owns Cardiovascular Systems stock?

Cardiovascular Systems' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Cortina Asset Management LLC (2.56%), Frontier Capital Management Co. LLC (2.45%), Point72 Asset Management L.P. (1.38%), New York State Common Retirement Fund (1.36%), Granahan Investment Management Inc. MA (0.90%) and Gabelli Funds LLC (0.66%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.

Who sold Cardiovascular Systems stock? Who is selling Cardiovascular Systems stock?

Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Gilder Gagnon Howe & Co. LLC, Ameriprise Financial Inc., American Century Companies Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, Frontier Capital Management Co. LLC and Monarch Partners Asset Management LLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.

Who bought Cardiovascular Systems stock? Who is buying Cardiovascular Systems stock?

Cardiovascular Systems' stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Gabelli Funds LLC, Cortina Asset Management LLC, Gamco Investors INC. ET AL, New York State Common Retirement Fund, Granahan Investment Management Inc. MA, Jennison Associates LLC and Trexquant Investment LP. Company insiders that have bought Cardiovascular Systems stock in the last two years include Camber Capital Management Llc and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.

How do I buy Cardiovascular Systems stock?

Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiovascular Systems' stock price today?

One share of Cardiovascular Systems stock can currently be purchased for approximately $24.38.

How big of a company is Cardiovascular Systems?

Cardiovascular Systems has a market capitalization of $831.89 million and generates $204.91 million in revenue each year. The medical device company earns ($1,790,000.00) in net income (profit) each year or ($0.06) on an earnings per share basis. Cardiovascular Systems employs 579 workers across the globe.

How can I contact Cardiovascular Systems?

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]


MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Cardiovascular Systems (NASDAQ:CSII)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $38.00 (55.87% upside)

Consensus Price Target History for Cardiovascular Systems (NASDAQ:CSII)

Price Target History for Cardiovascular Systems (NASDAQ:CSII)

Analysts' Ratings History for Cardiovascular Systems (NASDAQ:CSII)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/26/2017Needham & Company LLCReiterated RatingBuy$37.00 -> $36.00N/AView Rating Details
9/22/2017Raymond James Financial, Inc.Initiated CoverageMkt Perform -> Market PerformLowView Rating Details
9/21/2017Citigroup Inc.Initiated CoverageMarket PerformLowView Rating Details
6/21/2017Bank of America CorporationDowngradeNeutral -> UnderperformLowView Rating Details
1/30/2017Lake Street CapitalInitiated CoverageBuy$40.00N/AView Rating Details
11/15/2016Leerink SwannReiterated RatingOutperform$30.00N/AView Rating Details
10/27/2016Feltl & Co.UpgradeBuy -> Strong-Buy$30.00N/AView Rating Details
10/7/2016JMP SecuritiesInitiated CoverageOutperform$35.00N/AView Rating Details
12/23/2015Northcoast ResearchInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Cardiovascular Systems (NASDAQ:CSII)

Earnings by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Earnings History by Quarter for Cardiovascular Systems (NASDAQ CSII)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/23/2018($0.02)N/AView Earnings Details
10/25/2017Q1 2018($0.08)($0.06)$51.00 million$49.70 millionViewN/AView Earnings Details
8/2/2017Q4 2017($0.05)$0.02$51.98 million$52.90 millionViewListenView Earnings Details
5/3/2017Q3 2017($0.05)($0.05)$51.13 million$52.10 millionViewListenView Earnings Details
1/25/2017Q217($0.06)$0.03$49.72 million$50.00 millionViewN/AView Earnings Details
10/26/2016Q117($0.18)($0.06)$205.50 million$49.80 millionViewListenView Earnings Details
8/3/2016Q416($0.20)($0.15)$46.01 million$48.50 millionViewN/AView Earnings Details
5/4/2016Q316($0.54)($0.31)$42.13 million$44.50 millionViewN/AView Earnings Details
1/21/2016Q216($0.50)($0.47)$44.82 million$41.40 millionViewListenView Earnings Details
11/4/2015Q116($0.42)($0.41)$43.90 million$43.90 millionViewN/AView Earnings Details
8/5/2015Q415($0.30)($0.27)$50.10 million$48.50 millionViewN/AView Earnings Details
4/29/2015Q315($0.33)($0.34)$46.84 million$47.00 millionViewListenView Earnings Details
1/28/2015Q215($0.34)($0.17)$43.97 million$44.70 millionViewListenView Earnings Details
10/29/2014Q115($0.33)($0.26)$40.24 million$41.40 millionViewListenView Earnings Details
8/6/2014Q214($0.28)($0.31)$37.21 million$39.56 millionViewListenView Earnings Details
4/30/2014Q114($0.32)($0.32)$34.15 million$34.90 millionViewListenView Earnings Details
1/29/2014Q2($0.34)($0.32)$30.62 million$32.30 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.30)($0.28)$27.18 million$28.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cardiovascular Systems (NASDAQ:CSII)
2017 EPS Consensus Estimate: ($0.45)
2018 EPS Consensus Estimate: $0.10
2019 EPS Consensus Estimate: $0.23
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.44)($0.14)($0.26)
Q2 20174($0.26)($0.05)($0.11)
Q3 20174($0.05)($0.02)($0.04)
Q4 20174($0.06)($0.02)($0.04)
Q1 20184($0.08)$0.00($0.02)
Q2 20184($0.05)$0.03$0.01
Q3 20183$0.04$0.05$0.04
Q4 20184$0.05$0.09$0.08
Q1 20191($0.02)($0.02)($0.02)
Q2 20191$0.04$0.04$0.04
Q3 20191$0.10$0.10$0.10
Q4 20191$0.11$0.11$0.11
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cardiovascular Systems (NASDAQ:CSII)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cardiovascular Systems (NASDAQ CSII)

Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 72.09%
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Insider Trades by Quarter for Cardiovascular Systems (NASDAQ CSII)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017Edward M BrownDirectorSell20,000$29.16$583,200.00View SEC Filing  
8/30/2017Edward M BrownDirectorSell13,031$29.09$379,071.79View SEC Filing  
8/17/2017Laura GillundInsiderSell2,350$30.42$71,487.00View SEC Filing  
8/17/2017Scott R WardCEOSell5,529$30.41$168,136.89View SEC Filing  
8/16/2017Alexander RosensteinGeneral CounselSell979$30.71$30,065.09View SEC Filing  
8/16/2017Kevin J KennyCOOSell4,733$30.74$145,492.42View SEC Filing  
8/16/2017Laurence L BetterleyCFOSell4,443$30.74$136,577.82View SEC Filing  
5/17/2017Alexander RosensteinGeneral CounselSell219$32.30$7,073.70View SEC Filing  
11/18/2016Alexander RosensteinGeneral CounselSell529$26.80$14,177.20View SEC Filing  
11/18/2016Edward M BrownDirectorSell10,000$26.78$267,800.00View SEC Filing  
11/18/2016Laura GillundInsiderSell1,268$26.79$33,969.72View SEC Filing  
11/15/2016Edward M BrownDirectorSell10,000$24.95$249,500.00View SEC Filing  
10/10/2016Paul A KoehnSVPSell30,910$25.07$774,913.70View SEC Filing  
9/20/2016Camber Capital Management LlcMajor ShareholderSell1,100,000$23.26$25,586,000.00View SEC Filing  
9/7/2016Paul A KoehnSVPSell5,969$25.02$149,344.38View SEC Filing  
8/22/2016Alexander RosensteinGeneral CounselSell234$23.82$5,573.88View SEC Filing  
8/22/2016Kevin J KennyCOOSell3,166$23.95$75,825.70View SEC Filing  
8/22/2016Laura GillundInsiderSell1,395$23.93$33,382.35View SEC Filing  
8/22/2016Laurence L BetterleyCFOSell3,568$23.96$85,489.28View SEC Filing  
8/22/2016Paul A KoehnSVPSell2,527$23.92$60,445.84View SEC Filing  
8/17/2016Paul A KoehnSVPSell4,000$22.17$88,680.00View SEC Filing  
2/26/2016Paul A KoehnSVPSell956$38.79$37,083.24View SEC Filing  
2/23/2016Camber Capital Management LlcMajor ShareholderBuy250,000$7.55$1,887,500.00View SEC Filing  
1/25/2016Scott R WardCEOBuy2,700$9.30$25,110.00View SEC Filing  
10/2/2015Robert J. ThatcherinsiderSell64,700$16.31$1,055,257.00View SEC Filing  
9/2/2015David MartinCEOSell19,646$23.81$467,771.26View SEC Filing  
9/1/2015Kevin J KennyCOOSell5,289$23.85$126,142.65View SEC Filing  
9/1/2015Laurence L BetterleyCFOSell9,597$23.96$229,944.12View SEC Filing  
9/1/2015Paul A KoehnSVPSell4,946$23.86$118,011.56View SEC Filing  
9/1/2015Robert J ThatcherInsiderSell5,282$23.85$125,975.70View SEC Filing  
8/18/2015David MartinCEOSell17,688$23.99$424,335.12View SEC Filing  
8/18/2015Kevin J. KennyCOOSell3,913$24.00$93,912.00View SEC Filing  
8/18/2015Laurence L BetterleyCFOSell8,476$24.00$203,424.00View SEC Filing  
8/18/2015Paul A. KoehnSVPSell4,402$23.99$105,603.98View SEC Filing  
8/18/2015Robert J. ThatcherinsiderSell2,960$23.99$71,010.40View SEC Filing  
8/12/2015Brent G BlackeyDirectorBuy2,500$22.74$56,850.00View SEC Filing  
5/28/2015Paul A KoehnSVPSell4,389$27.86$122,277.54View SEC Filing  
5/1/2015Brent G BlackeyDirectorBuy2,500$29.38$73,450.00View SEC Filing  
2/10/2015David MartinCEOSell7,500$35.85$268,875.00View SEC Filing  
2/5/2015David MartinCEOSell4,500$34.96$157,320.00View SEC Filing  
1/29/2015Kevin J KennyVPSell4,212$35.00$147,420.00View SEC Filing  
9/3/2014David MartinCEOSell10,248$28.85$295,654.80View SEC Filing  
9/3/2014Kevin J KennyVPSell3,528$28.85$101,782.80View SEC Filing  
9/3/2014Laurence L BetterleyCFOSell4,674$28.82$134,704.68View SEC Filing  
9/3/2014Paul A KoehnSVPSell2,612$28.85$75,356.20View SEC Filing  
9/3/2014Robert J ThatcherInsiderSell2,791$28.85$80,520.35View SEC Filing  
8/28/2014Paul A KoehnSVPSell1,315$28.82$37,898.30View SEC Filing  
8/22/2014David MartinCEOSell13,957$29.03$405,171.71View SEC Filing  
8/22/2014Kevin J KennyVPSell2,914$29.09$84,768.26View SEC Filing  
8/22/2014Laurence L BetterleyCFOSell6,578$29.02$190,893.56View SEC Filing  
8/22/2014Paul A KoehnSVPSell2,755$29.06$80,060.30View SEC Filing  
8/22/2014Robert J ThatcherInsiderSell3,225$29.06$93,718.50View SEC Filing  
8/19/2014David MartinCEOSell11,754$29.28$344,157.12View SEC Filing  
8/19/2014Kevin J KennyVPSell2,117$29.28$61,985.76View SEC Filing  
8/19/2014Laurence L BetterleyCFOSell5,725$29.28$167,628.00View SEC Filing  
8/19/2014Paul A KoehnSVPSell2,168$29.28$63,479.04View SEC Filing  
8/19/2014Robert J ThatcherInsiderSell2,537$29.28$74,283.36View SEC Filing  
7/16/2014David MartinCEOSell10,703$28.83$308,567.49View SEC Filing  
7/16/2014Kevin J KennyVPSell3,007$28.83$86,691.81View SEC Filing  
7/16/2014Laurence L BetterleyCFOSell3,984$28.83$114,858.72View SEC Filing  
7/16/2014Paul A KoehnSVPSell2,716$28.83$78,302.28View SEC Filing  
7/16/2014Robert J ThatcherInsiderSell2,939$28.83$84,731.37View SEC Filing  
4/25/2014Kevin KennyVPSell15,484$28.79$445,784.36View SEC Filing  
2/24/2014David MartinCEOSell29,200$37.31$1,089,452.00View SEC Filing  
2/20/2014Kevin KennyVPSell6,779$36.02$244,179.58View SEC Filing  
1/30/2014David MartinCEOSell50,000$35.12$1,756,000.00View SEC Filing  
1/30/2014Robert ThatcherVPSell35,139$35.06$1,231,973.34View SEC Filing  
11/22/2013Robert ThatcherVPSell22,384$32.82$734,642.88View SEC Filing  
10/31/2013James E FlahertyInsiderSell34,819$30.35$1,056,756.65View SEC Filing  
10/23/2013David MartinCEOSell154,080$27.73$4,272,638.40View SEC Filing  
10/23/2013James E FlahertyInsiderSell36,682$26.85$984,911.70View SEC Filing  
10/23/2013Robert J ThatcherVPSell23,426$28.19$660,378.94View SEC Filing  
10/22/2013Kevin J KennyVPSell5,608$27.31$153,154.48View SEC Filing  
10/16/2013Kevin J KennyVPSell4,182$22.95$95,976.90View SEC Filing  
10/14/2013David MartinCEOSell21,170$22.00$465,740.00View SEC Filing  
9/20/2013David MartinCEOSell6,702$20.24$135,648.48View SEC Filing  
9/20/2013James FlahertyInsiderSell2,066$20.28$41,898.48View SEC Filing  
9/20/2013Robert ThatcherVPSell1,274$20.28$25,836.72View SEC Filing  
9/19/2013Laurence BetterleyCFOSell2,694$20.32$54,742.08View SEC Filing  
9/19/2013Paul KoehnSVPSell1,094$20.32$22,230.08View SEC Filing  
9/18/2013David MartinCEOSell8,030$20.94$168,148.20View SEC Filing  
9/18/2013James FlahertyInsiderSell2,970$20.94$62,191.80View SEC Filing  
9/18/2013Laurence BetterleyCFOSell4,324$20.93$90,501.32View SEC Filing  
9/18/2013Paul KoehnSVPSell1,732$20.93$36,250.76View SEC Filing  
9/18/2013Robert ThatcherVPSell1,731$20.94$36,247.14View SEC Filing  
9/10/2013John FriedmanDirectorSell48,273$20.73$1,000,699.29View SEC Filing  
8/30/2013David MartinCEOSell21,552$20.64$444,833.28View SEC Filing  
8/30/2013James FlahertyInsiderSell7,165$20.64$147,885.60View SEC Filing  
8/30/2013Kevin KennyVPSell1,899$20.64$39,195.36View SEC Filing  
8/30/2013Laurence BetterleyCFOSell8,692$20.64$179,402.88View SEC Filing  
8/27/2013David MartinCEOSell27,229$21.07$573,715.03View SEC Filing  
8/27/2013James FlahertyInsiderSell9,051$21.07$190,704.57View SEC Filing  
8/27/2013Kevin KennyVPSell2,396$21.07$50,483.72View SEC Filing  
8/27/2013Laurence BetterleyCFOSell10,982$21.07$231,390.74View SEC Filing  
8/16/2013James FlahertyInsiderSell1,255$20.51$25,740.05View SEC Filing  
8/16/2013Laurence BetterleyCFOSell1,568$20.51$32,159.68View SEC Filing  
8/14/2013James FlahertyInsiderSell4,902$21.31$104,461.62View SEC Filing  
8/13/2013Kevin KennyVPSell2,529$21.20$53,614.80View SEC Filing  
8/8/2013James FlahertyInsiderSell19,649$22.27$437,583.23View SEC Filing  
7/30/2013David MartinCEOSell11,094$19.69$218,440.86View SEC Filing  
7/30/2013Laurence L BetterleyCFOSell6,579$19.72$129,737.88View SEC Filing  
7/30/2013Robert J ThatcherVPSell3,112$19.86$61,804.32View SEC Filing  
6/3/2013James E FlahertyInsiderSell10,000$21.00$210,000.00View SEC Filing  
5/31/2013Paul A KoehnVPSell2,472$20.00$49,440.00View SEC Filing  
5/28/2013Kevin J KennyVPSell4,182$19.95$83,430.90View SEC Filing  
5/20/2013Glen D NelsonDirectorBuy10,250$18.47$189,317.50View SEC Filing  
5/16/2013Glen D NelsonDirectorBuy4,753$18.93$89,974.29View SEC Filing  
5/13/2013Glen D NelsonDirectorBuy18,393$18.11$333,097.23View SEC Filing  
11/13/2012Glen D NelsonDirectorBuy33,000$11.96$394,680.00View SEC Filing  
8/23/2012David MartinCEOSell10,510$9.07$95,325.70View SEC Filing  
8/23/2012James E FlahertyInsiderSell4,018$9.07$36,443.26View SEC Filing  
8/23/2012Laurence L BetterleyCFOSell4,770$9.07$43,263.90View SEC Filing  
8/23/2012Paul A KoehnVPSell2,496$9.07$22,638.72View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cardiovascular Systems (NASDAQ CSII)

Source:
DateHeadline
Cardiovascular Systems, Inc. (CSII) Given Consensus Recommendation of "Hold" by AnalystsCardiovascular Systems, Inc. (CSII) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 16 at 3:38 AM
Cardiovascular Systems, Inc. (CSII) Upgraded to "Hold" at Zacks Investment ResearchCardiovascular Systems, Inc. (CSII) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 13 at 12:41 PM
ETFs with exposure to Cardiovascular Systems, Inc. : November 8, 2017ETFs with exposure to Cardiovascular Systems, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 10:42 PM
Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: Q1, 2018 By the Numbers : November 7, 2017Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: Q1, 2018 By the Numbers : November 7, 2017
finance.yahoo.com - November 8 at 12:13 AM
 Analysts Anticipate Cardiovascular Systems, Inc. (CSII) Will Post Quarterly Sales of $53.25 Million Analysts Anticipate Cardiovascular Systems, Inc. (CSII) Will Post Quarterly Sales of $53.25 Million
www.americanbankingnews.com - November 1 at 5:54 PM
Contrasting Cardiovascular Systems (CSII) and The CompetitionContrasting Cardiovascular Systems (CSII) and The Competition
www.americanbankingnews.com - November 1 at 1:20 AM
Q2 2018 Earnings Forecast for Cardiovascular Systems, Inc. Issued By Leerink Swann (CSII)Q2 2018 Earnings Forecast for Cardiovascular Systems, Inc. Issued By Leerink Swann (CSII)
www.americanbankingnews.com - October 30 at 9:20 AM
Cardiovascular Systems, Inc. Reports Fiscal 2018 First-Quarter Financial Results - Business Wire (press release)Cardiovascular Systems, Inc. Reports Fiscal 2018 First-Quarter Financial Results - Business Wire (press release)
www.businesswire.com - October 28 at 12:13 AM
Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag - NasdaqCardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag - Nasdaq
www.nasdaq.com - October 28 at 12:13 AM
Leerink Swann Comments on Cardiovascular Systems, Inc.s FY2019 Earnings (CSII)Leerink Swann Comments on Cardiovascular Systems, Inc.'s FY2019 Earnings (CSII)
www.americanbankingnews.com - October 27 at 7:30 PM
Edited Transcript of CSII earnings conference call or presentation 25-Oct-17 8:45pm GMTEdited Transcript of CSII earnings conference call or presentation 25-Oct-17 8:45pm GMT
finance.yahoo.com - October 26 at 2:41 PM
Cardiovascular Systems, Inc. (CSII) Given "Buy" Rating at Needham & Company LLCCardiovascular Systems, Inc. (CSII) Given "Buy" Rating at Needham & Company LLC
www.americanbankingnews.com - October 26 at 7:38 AM
Cardiovascular Systems, Inc. (CSII) Issues  Earnings Results, Beats Expectations By $0.01 EPSCardiovascular Systems, Inc. (CSII) Issues Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - October 25 at 9:20 PM
Cardiovascular Systems, Inc. to Host Earnings CallCardiovascular Systems, Inc. to Host Earnings Call
finance.yahoo.com - October 25 at 7:10 PM
Cardiovascular Systems, Inc. Reports Fiscal 2018 First-Quarter Financial ResultsCardiovascular Systems, Inc. Reports Fiscal 2018 First-Quarter Financial Results
finance.yahoo.com - October 25 at 7:10 PM
Cardiovascular Systems reports 1Q lossCardiovascular Systems reports 1Q loss
finance.yahoo.com - October 25 at 7:10 PM
Cardiovascular Systems, Inc. (CSII) Releases Q2 Earnings GuidanceCardiovascular Systems, Inc. (CSII) Releases Q2 Earnings Guidance
www.americanbankingnews.com - October 25 at 6:04 PM
Cardiovascular Systems (CSII) vs. The Competition Head to Head SurveyCardiovascular Systems (CSII) vs. The Competition Head to Head Survey
www.americanbankingnews.com - October 24 at 2:16 PM
Cardiovascular Systems, Inc. (CSII) Receives Consensus Rating of "Hold" from AnalystsCardiovascular Systems, Inc. (CSII) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 4:40 AM
Head-To-Head Survey: Cardiovascular Systems (CSII) vs. Its CompetitorsHead-To-Head Survey: Cardiovascular Systems (CSII) vs. Its Competitors
www.americanbankingnews.com - October 20 at 12:32 AM
Cardiovascular Systems (CSII) and VWR Corporation (VWR) Head-To-Head ComparisonCardiovascular Systems (CSII) and VWR Corporation (VWR) Head-To-Head Comparison
www.americanbankingnews.com - October 18 at 2:24 PM
ETFs with exposure to Cardiovascular Systems, Inc. : October 17, 2017ETFs with exposure to Cardiovascular Systems, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 6:20 PM
Cardiovascular Systems, Inc. (CSII) to Release Quarterly Earnings on TuesdayCardiovascular Systems, Inc. (CSII) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 17 at 5:20 AM
Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular ... - PR Newswire (press release)Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular ... - PR Newswire (press release)
www.prnewswire.com - October 13 at 4:22 AM
Needham & Company LLC Reiterates "Buy" Rating for Cardiovascular Systems, Inc. (CSII)Needham & Company LLC Reiterates "Buy" Rating for Cardiovascular Systems, Inc. (CSII)
www.americanbankingnews.com - October 12 at 11:38 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cardiovascular Systems, Inc. for Potential ... - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cardiovascular Systems, Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - October 11 at 7:06 PM
-$0.07 Earnings Per Share Expected for Cardiovascular Systems, Inc. (CSII) This Quarter-$0.07 Earnings Per Share Expected for Cardiovascular Systems, Inc. (CSII) This Quarter
www.americanbankingnews.com - October 11 at 4:30 AM
Cardiovascular Systems, Inc. (CSII) Downgraded by Zacks Investment ResearchCardiovascular Systems, Inc. (CSII) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 10 at 10:46 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cardiovascular Systems, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cardiovascular Systems, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - October 9 at 3:53 PM
Financial Analysis: Cardiovascular Systems (CSII) versus The CompetitionFinancial Analysis: Cardiovascular Systems (CSII) versus The Competition
www.americanbankingnews.com - October 7 at 8:24 PM
ETFs with exposure to Cardiovascular Systems, Inc. : October 6, 2017ETFs with exposure to Cardiovascular Systems, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 5:48 PM
Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: Q4, 2017 By the Numbers : October 5, 2017Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: Q4, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 10:50 AM
Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular ... - Business Wire (press release)Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular ... - Business Wire (press release)
www.businesswire.com - October 4 at 4:16 PM
Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular Systems, Inc. (CSII)Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular Systems, Inc. (CSII)
finance.yahoo.com - October 4 at 4:16 PM
Scott Ward receives more than $5.2M in first full year as CEO of Cardiovascular Systems Inc.Scott Ward receives more than $5.2M in first full year as CEO of Cardiovascular Systems Inc.
www.bizjournals.com - October 4 at 11:34 AM
Cardiovascular Systems to Webcast Fiscal 2018 First-Quarter Earnings Conference Call Wednesday, October 25Cardiovascular Systems to Webcast Fiscal 2018 First-Quarter Earnings Conference Call Wednesday, October 25
finance.yahoo.com - October 4 at 11:34 AM
Reviewing Intersect ENT (XENT) and Cardiovascular Systems (CSII)Reviewing Intersect ENT (XENT) and Cardiovascular Systems (CSII)
www.americanbankingnews.com - September 27 at 10:36 AM
Cardiovascular Systems, Inc. (CSII) Receives Average Recommendation of "Hold" from BrokeragesCardiovascular Systems, Inc. (CSII) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 27 at 4:42 AM
Cardiovascular Systems, Inc. (CSII) Receives New Coverage from Analysts at Raymond James Financial, Inc.Cardiovascular Systems, Inc. (CSII) Receives New Coverage from Analysts at Raymond James Financial, Inc.
www.americanbankingnews.com - September 22 at 9:18 AM
Cardiovascular Systems, Inc. (CSII) Earns Market Perform Rating from Analysts at Citigroup Inc.Cardiovascular Systems, Inc. (CSII) Earns Market Perform Rating from Analysts at Citigroup Inc.
www.americanbankingnews.com - September 21 at 5:38 PM
Leerink Swann Equities Analysts Lower Earnings Estimates for Cardiovascular Systems, Inc. (CSII)Leerink Swann Equities Analysts Lower Earnings Estimates for Cardiovascular Systems, Inc. (CSII)
www.americanbankingnews.com - September 20 at 9:22 AM
Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance? - NasdaqWill Hurricanes Choke Cardiovascular (CSII) Q1 Performance? - Nasdaq
www.nasdaq.com - September 19 at 5:35 PM
Cardiovascular Systems, Inc. (CSII) Forecasted to Post Q2 2018 Earnings of ($0.01) Per ShareCardiovascular Systems, Inc. (CSII) Forecasted to Post Q2 2018 Earnings of ($0.01) Per Share
www.americanbankingnews.com - September 19 at 9:24 AM
Cardiovascular Systems Announces Anticipated Revenue Impact ... - Business Wire (press release)Cardiovascular Systems Announces Anticipated Revenue Impact ... - Business Wire (press release)
www.businesswire.com - September 18 at 10:36 PM
Cardiovascular Systems suffers a hurricane hangoverCardiovascular Systems suffers a hurricane hangover
www.bizjournals.com - September 18 at 5:34 PM
CSII Crosses Below Key Moving Average LevelCSII Crosses Below Key Moving Average Level
www.thestreet.com - September 18 at 5:34 PM
Commit To Purchase Cardiovascular Systems At $25, Earn 10.4% Annualized Using OptionsCommit To Purchase Cardiovascular Systems At $25, Earn 10.4% Annualized Using Options
www.nasdaq.com - September 14 at 6:25 PM
Cardiovascular Systems (CSII) Presents At Lake Street Capital Best Ideas Growth Conference - SlideshowCardiovascular Systems (CSII) Presents At Lake Street Capital Best Ideas Growth Conference - Slideshow
seekingalpha.com - September 14 at 6:25 PM
Cardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound? - NasdaqCardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - September 9 at 5:14 PM
Cardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound?Cardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 8 at 5:59 PM

Social Media

Financials

Chart

Cardiovascular Systems (NASDAQ CSII) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.